Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02306694 · ClinicalTrials.gov registry record · Phase 3
Prospective Biomarkers of Bone Metabolism in Hemophilia A
A Phase 3 study, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Phase 3
- Development phase
- 16
- Enrollment target
NCT02306694 is a Phase 3 study that has completed, run by Oregon Health and Science University. The registered enrollment target is 16 participants.
The verdict
NCT02306694, a Phase 3 study, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 16 participants
- Enrollment target
Study Summary
One of the major shortcomings in studying bone disease in hemophilia is the lack of fracture outcome data demonstrating the clinical significance of decreased BMD and altered bone biomarkers in the hemophilia population. This study demonstrates that PwH have an increased risk of fracture compared to the general population and that the issue of bone health will increase in importance as the PwH population ages.
Interventions
- DRUG Advate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2014-12 |
| Est. Completion | 2018-04-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02306694
The ClinicalTrials.gov registry entry for NCT02306694 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Advate is the first listed.
NCT02306694 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02306694 about?
NCT02306694 is a clinical study titled "Prospective Biomarkers of Bone Metabolism in Hemophilia A". One of the major shortcomings in studying bone disease in hemophilia is the lack of fracture outcome data demonstrating the clinical significance of decreased BMD and altered bone biomarkers in the hemophilia population. This study demonstrates that PwH have an increased risk of fracture compared to...
What is the current status of trial NCT02306694?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 16 participants. The study started on 2014-12. Estimated completion is 2018-04-16.
What interventions are being tested in trial NCT02306694?
The interventions under investigation include: Advate (DRUG).
Who is sponsoring clinical trial NCT02306694?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.